Managed Care Minute: May 2, 2015

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures underscores the need for targeted prevention strategies.

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

Sen. Bill Cassidy, MD, (R, Louisiana) holds a key vote on Robert F. Kennedy Jr's HHS Secretary confirmation. When Cassidy asked for a strategy on Medicare and Medicaid, Kennedy could not provide one.